DOCSLIB.ORG

Leukemia Lymphoma Myeloma 5Th International Congress

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Leukemia Lymphoma Myeloma 5Th International Congress 5 th International Congress on Leukemia – Lymphoma – Myeloma – Lymphoma International Congress on Leukemia 5th International Congress • on May 21 – 23, 2015 • Istanbul, Turkey Leukemia Lymphoma Myeloma May 21 - 23 İSTANBUL • 2015 TURKEY Proceedings & Abstract Book WOW Convention Center Proceedings & Abstract Book 5th International Congress on Leukemia – Lymphoma – Myeloma May 21 – 23, 2015 • Istanbul, Turkey Proceedings & Abstract Book Turkish Society of Hematology Organizing Committee Congress President Teoman Soysal Istanbul University, Cerrahpaşa School of Medicine, Department of Hematology, Istanbul, Turkey Congress Secretary Ahmet Muzaffer Demir Trakya University, School of Medicine, Department of Hematology, Edirne, Turkey İbrahim C. Haznedaroğlu Hacettepe University, School of Medicine, Department of Hematology, Ankara, Turkey Scientific Chairs - Program Planners Myelodysplastic Syndromes H. Joachim Deeg Fred Hutchinson Cancer Research Center, Seattle, USA Multipl Myeloma Angela Dispenzieri Division of Hematology, Mayo Clinic, Minnesota, USA Chronic Lymphocytic Leukemia Peter Dreger University of Heidelberg, Hamburg, Germany Hodgkin Lymphoma Andreas Engert Department of Internal Medicine, Cochrane Haematological Malignancies Group (CHMG), University Hospital Cologne, Cologne, Germany Diffuse Large B-Cell Lymphoma Christian Gisselbrecht Service d’Onco-Hématologie, Hôpital SaintLouis, Paris, France Acute Lymphoblastic Leukemia Nicola Gökbuget J.W. Goethe University Hospital, Frankfurt, Germany Folicular Lymphomas Burhan Ferhanoğlu Koç University Medical School, İstanbul, Turkey Chronic Myeloid Leukemia Richard A. Larson University Of Chicago, Chicago, USA Aggressive Lymphomas Anna Sureda Hospital de la Santa Creu i Sant Pau, Barcelona, Spain Acute Myeloid Leukemia Martin Tallman Memorial Sloan-Kettering Cancer Center, New York, USA Chronic Myeloproliferative Disorders Ayalew Tefferi Mayo Clinic, Mayo Graduate School of Medicine, Division of Hematology. Mayo Clinic, Minnesota, USA Meeting the Challenge of Emerging Pathogens in Patients with Hematological Malignancies: Rational Approaches to Diagnosis, Treatment, and Prevention Thomas J. Walsh National Cancer Institute Bethesda, Bethesda, USA Surnames are in alphabetical order. 2 5th International Congress on Leukemia – Lymphoma – Myeloma Dear Colleagues, It gives us great pleasure to host the 5th International Congress on Leukemia, Lymphoma Myeloma (ICLLM 2015) in Istanbul, Turkey. The ICLLM2015 Congress provides a unique forum for scientists and medical professionals gathered from around the world to meet and exchange ideas and information in the fields of hematology and oncology. The scientific program of the ICLLM Congress boasts most of the hematology masters who aim to provide a perfect balance between clinical education and news of the latest scientific developments. There are 12 scientific sessions, 3 satellite symposia and 3 meet the expert sessions with 12 scientific chair with a total 49 chair and speakers. New diagnosis and treatment strategies of the malignant hematological diseases will be discussed with every aspect besides the standard therapies. Istanbul as the capital of culture in Europe for 2010 started to associate with culture and the arts all over the world. Istanbul will achieve lasting gains in the fields of urban renewal, urban living and environmental and social development. Those who come to Istanbul for cultural and artistic projects will visit the city’s cultural riches, mosques, churches, palaces and museums. The cultural program also promises to be special, highlighting Istanbul’s proud culture and national heritage. Istanbul has been inhabited since the end of the 4th century B.C. Remains from the Hellenic, Roman, Byzantine and Ottoman periods are scattered throughout the city, prominent among them the Hagia Sophia, Basilica Cistern, Blue Mosque, Grand Bazaar, Topkapı Palace and Turkish Baths, making Istanbul a fascinating open air museum. You would have the opportunity to discover Turkish music, art and architecture, enjoy the delicious tastes of Turkish and Ottoman cuisine, and experience the world famous Turkish hospitality. The unique geography of Istanbul gives the opportunity to meet where the two continents meet. The Istanbul Wow Convention Center, located near the airport and easily accessible by public transport, offers excellent facilities, including all the necessary infrastructure and professionalism to successfully host a medical convention of this import. Participants from 22 countries are registered, and the Congress has been accredited by both the European Hematology Association (EHA) and the Turkish Medical Association. On behalf of the Board of the Turkish Society of Hematology and scientific faculty, I would like to welcome you to the 5th International Congress on Leukemia-Myeloma-Lymphoma. I believe that you will enjoy both the scientific and cultural aspects of the program, and that you also take advantage of the pleasure of the nice İstanbul spring. Prof. Dr. Teoman Soysal Congress President May 21 – 23, 2015 • Istanbul, Turkey 3 Dear Colleagues, It is great honor for me to invite you to the 5th International Congress on Leukemia, Lymphoma, Myeloma (ICLLM 2015). Scientific level of ICLLM congresses has been improving progressively year by year. I believe that this conference will represent the challenge the development of the basic studies as well as clinical researches of Hematology. The abstracts and the educational lectures have been designated to establish an area suitable for the exchange of ideas during the meeting days. There are 124 abstracts from 13 different countries. The full text content of the educational books of the meetings of International Congress on Leukemia Lymphoma Myeloma (ICLLM), will be available in the website of Turkish Society of Hematology (www.thd.org.tr) just after the end of the conference. During its long history, Istanbul has served as the Capital of the Roman Empire, the East Roman (Byzantine) Empire, the Latin Empire, and the Ottoman Empire. Located in the center of the old world, this exotic city is famous for its historical monuments and scenic views. It is the only city in the world which spreads over two continents: Asia and Europe which are separated by a narrow strait - the Bosphorus. Even if you spend only a short time in Istanbul, you can see much ofthis great heritage. Although renowned for its mystery and history, Istanbul is also a rapidly modernising country with a prime location; one foot in Europe and one in the East. Thus Istanbul retains its fascinating differences, and its contradictions: mosques coexist with churches, and remnants of the Roman Empire still stand alongside ancient Hittite and Neolithic sites. We are so glad to welcome you in this beautiful city. Best regards. Prof. Dr. Ahmet Muzaffer Demir On behalf of Congress Secretariat 4 5th International Congress on Leukemia – Lymphoma – Myeloma Contents Organizing Committee ........................................................................ 2 Scientific Program ................................................................................. 7 May 21, 2015, Thursday ................................................. 8 May 22, 2015, Wednesday ............................................ 10 May 23, 2015, Friday ....................................................... 12 Proceedings ............................................................................................. 17 Acute Myeloid Leukemia ................................................ 17 Multiple Myeloma ............................................................ 24 Diffuse Large B-Cell Lymphoma ................................... 27 Cutting Edge Advances in Myeloproliferative Neoplasms ......................................................................... 35 Acute Lymphoblastic Leukemia .................................... 40 Hodgkin Lymphoma ........................................................ 46 Meeting the Challenge of Emerging Pathogens in Patients with Hematological Malignancies: Advances in Diagnosis, Treatment and Prevention . 50 Myelodysplastic Syndromes .......................................... 76 Follicular Lymphoma ....................................................... 87 Chronic Myeloid Leukemia ............................................. 94 Chronic Lymphocytic Leukemia .................................... 106 Aggressive Lymphomas .................................................. 112 Abstracts ................................................................................................ 119 Author Index ........................................................................................... 203 May 21 – 23, 2015 • Istanbul, Turkey 5 TURKISH SOCIETY OF HEMATOLOGY BOARD OF DIRECTORS President: Prof. Dr. Teoman Soysal Vice President: Prof. Dr. Hale Ören General Secretary: Prof. Dr. Ahmet Muzaffer Demir Research Secretary: Prof. Dr. İbrahim C. Haznedaroğlu Treasurer: Prof. Dr. Fahir Özkalemkaş Member: Prof. Dr. Ali Zahit Bolaman Member: Prof. Dr. Mehmet Sönmez TURKISH SOCIETY OF HEMATOLOGY Address: Çobançeşme Sanayi Caddesi No:44 Nish İstanbul Rezidans C Blok 12. Kat No:140 Bahçelievler, İstanbul / Turkey Phone: +90 212 603 66 55 Fax: +90 212 603 66 35 E-mail: [email protected] Url: www.thd.org.tr Address: Turan Güneş Bulv. Sancak Mah. 613. Sok. No:8, Çankaya- Ankara / Turkey Phone: +90 312 490 98 97 Fax: +90 312 490 98 68 E-mail: [email protected] Url: www.thd.org.tr Organization Services SERENAS INTERNATIONAL
Load more

Recommended publications
  • Increased Nuchal Translucency Precision Panel
    Increased Nuchal Translucency Precision Panel Overview Increased Nuchal Translucency (NT) is defined as an abnormal accumulation of fluid in the nuchal area, which is visualized as a thickened sonolucent area. It is a standardized measure obtained between 11 and 14 weeks of gestation to calculate the risk of a fetus being affected by a chromosomal aneuploidy. NT>3.5mm has been found to be associated with fetal chromosomal abnormalities and single-gene disorders as well as cardiac defects and other structural abnormalities in euploid and aneuploid fetuses. Proportionally as NT increases, even with a normal karyotype, there is a higher risk of adverse pregnancy outcomes such as miscarriage, intrauterine death, congenital heart defects and numerous other structural and genetic syndromes. There is not one single cause of increased NT, it is based on a complex and multifactorial process, linked to one or more embryonic processes. It has been shown that a persistently increased NT with a normal karyotype and aCGH has a 4-10% probability of being associated to Noonan Syndrome and/or other RASopathies using Whole Exome Sequencing (WES). However, the general tendency following detection of isolated enlarged NT in an euploid fetus is that most babies with normal detailed ultrasound examination and echocardiography will have uneventful outcomes. The Igenomix Increased Nuchal Translucency Precision Panel can be used to make a directed and accurate prenatal differential diagnosis of increased nuchal translucency in patients with or without a normal karyotype ultimately leading to a better management and prognosis of the associated comorbidities. It provides a comprehensive analysis of the genes involved in this disease using next-generation sequencing (NGS) to fully understand the spectrum of relevant genes involved.
    [Show full text]
  • Clinical Use of Proteasome Inhibitors in the Treatment of Multiple Myeloma
    Pharmaceuticals 2015, 8, 1-20; doi:10.3390/ph8010001 OPEN ACCESS pharmaceuticals ISSN 1424-8247 www.mdpi.com/journal/pharmaceuticals Review Clinical Use of Proteasome Inhibitors in the Treatment of Multiple Myeloma Noah M. Merin and Kevin R. Kelly * Internal Medicine, Jane Anne Nohl Division of Hematology, Keck School of Medicine of University of Southern California, Los Angeles, CA 90033, USA; E-Mail: [email protected] * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +1-323-865-3823; Fax: +1-323-865-0060. Academic Editor: Jennifer Carew Received: 29 July 2014 / Accepted: 4 December 2014 / Published: 24 December 2014 Abstract: Multiple myeloma (MM) is an incurable hematological malignancy characterized by the clonal proliferation of neoplastic plasma cells. The use of proteasome inhibitors in the treatment of MM has led to significant improvements in outcomes. This article reviews data on the use of the two approved proteasome inhibitors (bortezomib and carlfilzomib), as well as newer agents under development. Emphasis is placed on the clinical use of proteasome inhibitors, including management of side effects and combination with other agents. Keywords: multiple myeloma; proteasome inhibitors; toxicity 1. Introduction Multiple myeloma (MM) is a malignant neoplasm characterized by clonal proliferation of plasma cells in the bone marrow that produce monoclonal protein (M-protein) that may be detected in the serum or urine. It is the second most common hematologic cancer in the United States (after Non-Hodgkin Lymphoma); an estimated 24,050 new cases and 11,090 deaths will occur due to MM in the USA in 2014 [1].
    [Show full text]
  • Research in Your Backyard Developing Cures, Creating Jobs
    Research in Your Backyard Developing Cures, Creating Jobs PHARMACEUTICAL CLINICAL TRIALS IN ILLINOIS Dots show locations of clinical trials in the state. Executive Summary This report shows that biopharmaceutical research com- Quite often, biopharmaceutical companies hire local panies continue to be vitally important to the economy research institutions to conduct the tests and in Illinois, and patient health in Illinois, despite the recession. they help to bolster local economies in communities all over the state, including Chicago, Decatur, Joliet, Peoria, At a time when the state still faces significant economic Quincy, Rock Island, Rockford and Springfield. challenges, biopharmaceutical research companies are conducting or have conducted more than 4,300 clinical For patients, the trials offer another potential therapeutic trials of new medicines in collaboration with the state’s option. Clinical tests may provide a new avenue of care for clinical research centers, university medical schools and some chronic disease sufferers who are still searching for hospitals. Of the more than 4,300 clinical trials, 2,334 the medicines that are best for them. More than 470 of the target or have targeted the nation’s six most debilitating trials underway in Illinois are still recruiting patients. chronic diseases—asthma, cancer, diabetes, heart dis- ease, mental illnesses and stroke. Participants in clinical trials can: What are Clinical Trials? • Play an active role in their health care. • Gain access to new research treatments before they In the development of new medicines, clinical trials are are widely available. conducted to prove therapeutic safety and effectiveness and compile the evidence needed for the Food and Drug • Obtain expert medical care at leading health care Administration to approve treatments.
    [Show full text]
  • A Phase 1 Dose-Escalation Study of Filanesib Plus
    A Phase 1 Dose-Escalation Study of Filanesib Plus Bortezomib and Dexamethasone in Patients With Recurrent/ Refractory Multiple Myeloma Ajai Chari, Icahn School of Medicine at Mount Sinai Myo Htut, City Hope National Medical Center Jeffrey A. Zonder, Wayne State University Joseph W. Fay, Baylor Research Institute Andrzej Jakubowiak, University of Chicago Joan B. Levy, Multiple Myeloma Research Consortium Kenneth Lau, Icahn School of Medicine at Mount Sinai Steven M. Burt, Wayne State University Brian J. Tunquist, Array BioPharma Inc Brandi W. Hilder, Array BioPharma Inc Only first 10 authors above; see publication for full author list. Journal Title: Cancer Volume: Volume 122, Number 21 Publisher: Wiley | 2016-11-01, Pages 3327-3335 Type of Work: Article | Post-print: After Peer Review Publisher DOI: 10.1002/cncr.30174 Permanent URL: https://pid.emory.edu/ark:/25593/vj1mj Final published version: http://dx.doi.org/10.1002/cncr.30174 Copyright information: © 2016 American Cancer Society Accessed October 1, 2021 7:46 AM EDT HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Cancer. Manuscript Author Author manuscript; Manuscript Author available in PMC 2019 November 15. Published in final edited form as: Cancer. 2016 November 15; 122(21): 3327–3335. doi:10.1002/cncr.30174. A Phase 1 Dose-Escalation Study of Filanesib Plus Bortezomib and Dexamethasone in Patients With Recurrent/Refractory Multiple Myeloma Ajai Chari, MD1, Myo Htut, MD2, Jeffrey A. Zonder, MD3, Joseph W. Fay, MD4, Andrzej J. Jakubowiak, MD5, Joan B. Levy, PhD6, Kenneth Lau, BA1, Steven M. Burt, MSN, NP-C3, Brian J. Tunquist, PhD7, Brandi W. Hilder, PhD7, Selena A.
    [Show full text]
  • POEMS Syndrome: an Atypical Presentation with Chronic Diarrhoea and Asthenia
    European Journal of Case Reports in Internal Medicine POEMS Syndrome: an Atypical Presentation with Chronic Diarrhoea and Asthenia Joana Alves Vaz1, Lilia Frada2, Maria Manuela Soares1, Alberto Mello e Silva1 1 Department of Internal Medicine, Egas Moniz Hospital, Lisbon, Portugal 2 Department of Gynecology and Obstetrics, Espirito Santo Hospital, Evora, Portugal Doi: 10.12890/2019_001241 - European Journal of Case Reports in Internal Medicine - © EFIM 2019 Received: 28/07/2019 Accepted: 13/11/2019 Published: 16/12/2019 How to cite this article: Alves Vaz J, Frada L, Soares MM, Mello e Silva A. POEMS syndrome: an atypical presentation with chronic diarrhoea and astenia. EJCRIM 2019;7: doi:10.12890/2019_001241. Conflicts of Interests: The Authors declare that there are no competing interest This article is licensed under a Commons Attribution Non-Commercial 4.0 License ABSTRACT POEMS syndrome is a rare paraneoplastic condition associated with polyneuropathy, organomegaly, monoclonal gammopathy, endocrine and skin changes. We report a case of a man with Castleman disease and monoclonal gammopathy, with a history of chronic diarrhoea and asthenia. Gastrointestinal involvement in POEMS syndrome is not frequently referred to in the literature and its physiopathology is not fully understood. Diagnostic criteria were met during hospitalization but considering the patient’s overall health condition, therapeutic options were limited. Current treatment for POEMS syndrome depends on the management of the underlying plasma cell disorder. This report outlines the importance of a thorough review of systems and a physical examination to allow an attempted diagnosis and appropriate treatment. LEARNING POINTS • POEMS syndrome should be suspected in the presence of peripheral polyneuropathy associated with monoclonal gammopathy; diagnostic workup is challenging and delay in treatment is very common.
    [Show full text]
  • An Insight Toward Experienced Reality
    Power Struggles in the Production of and Changing Perceptions over the Contemporary Public Space: An Insight toward Experienced Reality Thesis presented for the degree of Doctor of Philosophy at the Newcastle University Tugce Sanli School of Architecture, Planning and Landscape January 2016 Abstract Cities have been invaded by the tools of the capitalist systems which transform the built environment while leaving the scars of this transformation on the societies. The demands of market forces generate new life styles and social contexts reshaped via relations of power and expression of political and economic hegemony. The nature of urban landscape, particularly the condition of public spaces, has shifted towards most profitable use while private interests have taken over public spaces and contemporary public spaces have emerged such as shopping malls. This study contributes to the debates that explore the ‘veiled’ side of planning and hegemonic relations of power in decision making processes that actually in a strong relation with cultural structuring and traditional praxis of a community. In addition, the study has a comprehensive approach by exploring societal influences emerging through power relations and their reflections on contemporary public spaces via exploring perceptions. The study conducts an investigation using qualitative methods and adopting case study approach via three shopping malls from Ankara (Turkey) to answer how urban power relations are generated and become effective on planning and production of contemporary public spaces and how the perceptions upon these public spaces are being transformed? Therefore, the study is founded on two main themes as pillars: power relations and public spaces. In addition, the empirical chapters at the end are set in parallel with the research objectives and data is gathered via archive analysis of the municipalities and interviews conducted with key informants and users of the selected cases.
    [Show full text]
  • The Showgirl Goes On
    Star_Jan02_p1-20_Layout 1 1/2/2013 3:31 PM Page 1 ONLINE GET SELECT CONTENT ON THE GO, WWW.MONTROSE-STAR.COM IS MOBILE ENABLED! The WWW.MONTROSE-STAR.COM YOUR GUIDE TO GLBT ENTERTAINMENT, RECREATION & CULTURE IN CENTRAL AND COASTAL TEXAS WEDNESDAY, JANUARY 2, 2013 H VOL. III, ISSUE 20 FEATURE n19 One Good Love CALENDAR n6 Next2Weeks! DINING GUIDE n14 Roots Juice Drink Your Veggies! COMMUNITY n6 HAPPY NEW YEAR! The Showgirl INDEX Editorial........................4 Non-Profits Calendar .....16 Goes On Cartoons ....................33 Crossword ..................33 p10 Lifestyles ....................31 Star_Jan02_p1-20_Layout 1 1/2/2013 2:58 PM Page 2 Page 2 Montrose Star H Wednesday, January 2, 2013 www.Montrose-Star.com H also find us onn F Facebook.com/Star.Montrose Star_Jan02_p1-20_Layout 1 1/2/2013 2:58 PM Page 3 Montrose Star H Wednesday, January 2, 2013 Page 3 www.Montrose-Star.com H also find us onn F Facebook.com/Star.Montrose Star_Jan02_p1-20_Layout 1 1/2/2013 2:58 PM Page 4 Page 4 Montrose Star H Wednesday, January 2, 2013 Op-ED CONTACT US: 713-942-0084 EMAIL: [email protected] publisher Executive Editor Health & Fitness Music Laura M. Villagrán Kenton Alan DJ Chris Allen Sales Director Davey Wavey DJ JD Arnold Angela K. Snell Dr. Randy Mitchmore DJ Mark DeLange Creep of the Week: production News & Features DJ Wild & DJ Jeff Rafael Espinosa Johnny Trlica Scene Writers Circulation & Distribution Jim Ayers Arts Reviews Miriam Orihuela Pope Benedic XVI Daddy Bob Bill O’Rourke & Loyal K Elizabeth Membrillo Stephen Hill Lifestyles Rey Lopez Gayl Newton By d’anne WitkoWski lent to a suicide bomber.
    [Show full text]
  • Chemotherapeutic Treatment of Acute Myeloid Leukemia
    Clinical Trial Outcomes Mahdi, Mahdi & Knapper Chemotherapeutic treatment of acute myeloid leukemia 5 Clinical Trial Outcomes Chemotherapeutic treatment of acute myeloid leukemia: incorporating the results of recent clinical trials Clin. Invest. (Lond.) Better outcomes for patients with acute myeloid leukemia over the last 30 years have Ali J Mahdi*,1, Eamon J been largely achieved by improvements in supportive care measures rather than Mahdi1 & Steven Knapper1 therapeutic advances. The combination of daunorubicin and cytarabine has remained 1Cardiff University School of Medicine, Hematology Department, Heath Park, the standard of care for patients undergoing intensive induction–consolidation Cardiff CF14 4XN, UK treatment. In less fit older patients, low-dose cytarabine is the equivalent, although *Author for correspondence: the hypomethylating agent azacitidine may be challenging current practice. [email protected] Enhanced understanding of disease pathogenesis and therapy resistance has enabled the entry of novel chemotherapeutic and nonchemotherapeutic agents into clinical development with varied levels of activity. This article examines the evidence behind established chemotherapy practices for intensive and nonintensive acute myeloid leukemia treatments with an emphasis on emerging clinical trial data from novel chemotherapeutic and nonchemotherapeutic agents. Keywords: acute myeloid leukemia • aminopeptidase inhibitors • farnesyl transferase inhibitors • FLT3 inhibitors • gemtuzumab ozogamicin • histone deacytylase inhibitors • hypomethylating • Polo-like kinase 1 inhibitors Methodology AML cases [7]. Older patients over the age of 10.4155/CLI.14.112 An electronic database search (EMBASE, 60 years thus represent an important popula- MEDLINE and PubMed) was undertaken tion from both demographic and therapeutic to identify and review clinical studies in perspectives. Older patients frequently have acute myeloid leukemia (AML) undertaken multiple comorbidities, unfavorable cyto- between 1 January 2009 and 1 June 2014.
    [Show full text]
  • Draft COMP Agenda 16-18 January 2018
    12 January 2018 EMA/COMP/818236/2017 Inspections, Human Medicines Pharmacovigilance and Committees Committee for Orphan Medicinal Products (COMP) Draft agenda for the meeting on 16-18 January 2018 Chair: Bruno Sepodes – Vice-Chair: Lesley Greene 16 January 2018, 09:00-19:30, room 2F 17 January 2018, 08:30-19:30, room 2F 18 January 2018, 08:30-18:30, room 2F Health and safety information In accordance with the Agency’s health and safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting. Disclaimers Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the COMP meeting reports once the procedures are finalised. Of note, this agenda is a working document primarily designed for COMP members and the work the Committee undertakes. Note on access to documents Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on- going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).
    [Show full text]
  • Orphanet Report Series Rare Diseases Collection
    Marche des Maladies Rares – Alliance Maladies Rares Orphanet Report Series Rare Diseases collection DecemberOctober 2013 2009 List of rare diseases and synonyms Listed in alphabetical order www.orpha.net 20102206 Rare diseases listed in alphabetical order ORPHA ORPHA ORPHA Disease name Disease name Disease name Number Number Number 289157 1-alpha-hydroxylase deficiency 309127 3-hydroxyacyl-CoA dehydrogenase 228384 5q14.3 microdeletion syndrome deficiency 293948 1p21.3 microdeletion syndrome 314655 5q31.3 microdeletion syndrome 939 3-hydroxyisobutyric aciduria 1606 1p36 deletion syndrome 228415 5q35 microduplication syndrome 2616 3M syndrome 250989 1q21.1 microdeletion syndrome 96125 6p subtelomeric deletion syndrome 2616 3-M syndrome 250994 1q21.1 microduplication syndrome 251046 6p22 microdeletion syndrome 293843 3MC syndrome 250999 1q41q42 microdeletion syndrome 96125 6p25 microdeletion syndrome 6 3-methylcrotonylglycinuria 250999 1q41-q42 microdeletion syndrome 99135 6-phosphogluconate dehydrogenase 67046 3-methylglutaconic aciduria type 1 deficiency 238769 1q44 microdeletion syndrome 111 3-methylglutaconic aciduria type 2 13 6-pyruvoyl-tetrahydropterin synthase 976 2,8 dihydroxyadenine urolithiasis deficiency 67047 3-methylglutaconic aciduria type 3 869 2A syndrome 75857 6q terminal deletion 67048 3-methylglutaconic aciduria type 4 79154 2-aminoadipic 2-oxoadipic aciduria 171829 6q16 deletion syndrome 66634 3-methylglutaconic aciduria type 5 19 2-hydroxyglutaric acidemia 251056 6q25 microdeletion syndrome 352328 3-methylglutaconic
    [Show full text]
  • Синергистички Ефекат Блокаде Il-33/St2 И Pdl/Pd-1 Осовина На Прогресију Мишјег Карцинома Дојке
    УНИВЕРЗИТЕТ У КРАГУЈЕВЦУ ФАКУЛТЕТ МЕДИЦИНСКИХ НАУКА Марина Јовановић Синергистички ефекат блокаде IL-33/ST2 и PDL/PD-1 осовина на прогресију мишјег карцинома дојке ДОКТОРСКА ДИСЕРТАЦИЈА КРАГУЈЕВАЦ, 2021. UNIVERSITY OF KRAGUJEVAC FACULTY OF MEDICAL SCIENCES Marina Jovanovic Synergistical effect of IL-33/ST2 and PDL/PD-1 blockage in a mammary carcinoma Doctoral Dissertation KRAGUJEVAC, 2021. Идентификациона страница докторске дисертације Аутор Име и презиме: Марина Јовановић Датум и место рођења: 21.11.1991. Ћуприја Садашње запослење: Клинички центар Крагујевац, специјализант оториноларингологије Докторска дисертација Наслов: Синергистички ефекат блокаде IL-33/ST2 и PDL/PD-1 осовина на прогресију мишјег карцинома дојке Број страница: 138 Број слика: 55 (53 графикона, 2 табеле) Број библиографских података: 312 Установа и место где је рад израђен: Факултет медицинских наука у Крагујевцу Научна област (УДК): Медицина Ментор: Проф. др Иван Јовановић, ванредни професор Факултета медицинских наука Универзитета у Крагујевцу за уже научне области Микробиологија и имунологија, Онкологија Оцена и одбрана Датум пријаве теме: Број одлуке и датум прихватања теме докторске/уметничке дисертације: IV-03-65/21 од 04.09.2019. године Комисија за оцену научне заснованости теме и испуњености услова кандидата: 1. Проф. др Небојша Арсенијевић, редовни професор Факултета медицинских наука Универзитета у Крагујевцу за уже научне области Микробиологија и имунологија; Онкологијa, председник 2. Проф. др Гордана Радосављевић, ванредни професор Факултета медицинских наука Универзитета у Крагујевцу за ужу научну област Микробиологија и имунологија, члан 3. Доц. др Милан Јовановић, доцент Медицинског факултета Војномедицинске академије Универзитета одбране у Београду за ужу научну област Хирургија, члан Комисија за оцену и одбрану докторске/уметничке дисертације: Датум одбране дисертације: 1 Doctoral dissertation identification page Author Name and surname: Marina Jovanovic Date and place of birth: 21.11.1991.
    [Show full text]
  • EJTS European Journal of Transformation Studies 2020, Vol.8, Supplement 1
    EJTS European Journal of Transformation Studies 2020, Vol.8, Supplement 1 1 EJTS European Journal of Transformation Studies 2020, Vol.8, Supplement 1 EUROPEAN JOURNAL OF TRANSFORMATION STUDIES 2020 Vol. 8 Supplement 1 © by Europe Our House, Tbilisi e-ISSN 2298-0997 2 EJTS European Journal of Transformation Studies 2020, Vol.8, Supplement 1 Arkadiusz Modrzejewski University of Gdansk, Poland [email protected] Editors Tamar Gamkrelidze Europe Our House, Tbilisi, Georgia Tatiana Tökölyová Ss. Cyril and Methodius University in Trnava, Slovakia Rafał Raczyński Research Institute for European Policy, Poland Paweł Nieczuja–Ostrowski – executive editor Pomeranian University in Slupsk, Poland Jaroslav Mihálik – deputy editor Ss. Cyril and Methodius University in Trnava, Slovakia Edita Poórová – copy editor Ss. Cyril and Methodius University in Trnava, Slovakia Andrii Kutsyk– assistant editor Lesya Ukrainka Eastern European National University, Lutsk, Ukraine Editorial Advisory Board Prof. Jakub Potulski,University of Gdansk, Poland – chairperson Prof. Tadeusz Dmochowski,University of Gdansk, Poland Prof. Slavomír Gálik, University of Ss.Cyril and Methodius in Trnava, Slovakia Prof. Wojciech Forysinski, Eastern Mediterranean University, Famangusta, Northern Cyprus Prof. Danuta Plecka, Zielona Gora University, Poland Prof. Anatoliy Kruglashov, Chernivtsi National University, Ukraine Prof. Malkhaz Matsaberidze, Ivane Javakashvili Tbilisi State University Prof. Ruizan Mekvabidze, Gori State Teaching University, Georgia Prof. Lucia Mokrá, Comenius University in Bratislava, Slovakia Prof. Andras Bozoki, Central European University in Budapest, Hungary Prof. Tereza - Brînduşa Palade, National University of Political and Public Administra- tion in Bucharest, Romania Prof. Elif Çolakoğlu, Atatürk University in Erzurum, Turkey Prof. Valeriu Mosneaga, Moldova State University in Chişinău, Republic of Moldova Prof. Andrei Taranu, National University of Political Science and Public Administration in Bucharest, Romania Prof.
    [Show full text]